Mepolizumab improved airway hyperresponsiveness in a patient with allergic bronchopulmonary aspergillosis.

IF 1.9 4区医学 Q3 ALLERGY

Asian Pacific journal of allergy and immunology Pub Date : 2025-06-01 DOI:10.12932/AP-030521-1125

Chisato Onitsuka, Tetsuya Homma, Tomoko Kawahara, Tomoyuki Kimura, Yoshito Miyata, Hironori Sagara

{"title":"Mepolizumab improved airway hyperresponsiveness in a patient with allergic bronchopulmonary aspergillosis.","authors":"Chisato Onitsuka, Tetsuya Homma, Tomoko Kawahara, Tomoyuki Kimura, Yoshito Miyata, Hironori Sagara","doi":"10.12932/AP-030521-1125","DOIUrl":null,"url":null,"abstract":"Background: Allergic bronchopulmonary aspergillosis (ABPA) is a severe type of asthma characterized by hypersensitivity to Aspergillus fumigatus and lung infiltration with eosinophilia. The central pathogenesis of asthma is airway hyperresponsiveness (AHR), with eosinophils playing a critical role. Anti-interleukin (IL)-5 antibody therapy has been recently introduced to treat severe asthma, which reportedly inactivates and reduces eosinophil count. A recent case series highlighted the improvement in asthmatic symptoms associated with ABPA, but previous reports failed to demonstrate any improvement in AHR.Objective: Herein, we aimed to elucidate the efficacy of mepolizumab in a patient with ABPA who showed improvement in AHR.Methods: Case report.Results: A 63-year-old Asian woman with ABPA showed improvement in asthmatic symptoms and AHR following mepolizumab therapy.Conclusions: Our results suggest that IL-5 may serve in the pathogenesis of ABPA.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"352-355"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific journal of allergy and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12932/AP-030521-1125","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Allergic bronchopulmonary aspergillosis (ABPA) is a severe type of asthma characterized by hypersensitivity to Aspergillus fumigatus and lung infiltration with eosinophilia. The central pathogenesis of asthma is airway hyperresponsiveness (AHR), with eosinophils playing a critical role. Anti-interleukin (IL)-5 antibody therapy has been recently introduced to treat severe asthma, which reportedly inactivates and reduces eosinophil count. A recent case series highlighted the improvement in asthmatic symptoms associated with ABPA, but previous reports failed to demonstrate any improvement in AHR.

Objective: Herein, we aimed to elucidate the efficacy of mepolizumab in a patient with ABPA who showed improvement in AHR.

Methods: Case report.

Results: A 63-year-old Asian woman with ABPA showed improvement in asthmatic symptoms and AHR following mepolizumab therapy.

Conclusions: Our results suggest that IL-5 may serve in the pathogenesis of ABPA.

查看原文本刊更多论文

美泊利珠单抗改善了一名过敏性支气管肺曲霉病患者的气道高反应性。

背景：过敏性支气管肺曲霉菌病（ABPA）是一种严重的哮喘类型，其特征是对烟曲霉菌过敏和肺部嗜酸性粒细胞浸润。哮喘的核心发病机制是气道高反应性（AHR），其中嗜酸性粒细胞起着关键作用。据报道，抗白细胞介素（IL）-5 抗体疗法可灭活和减少嗜酸性粒细胞的数量。最近的一个病例系列强调了与 ABPA 相关的哮喘症状的改善，但之前的报告未能证明嗜酸性粒细胞增多症有任何改善：方法：病例报告：结果：一名 63 岁的亚裔女性 ABPA 患者在接受甲泼尼单抗治疗后，哮喘症状和 AHR 均有所改善：我们的研究结果表明，IL-5可能是ABPA的发病机制之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific journal of allergy and immunology 医学-过敏

CiteScore

12.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Asian Pacific Journal of Allergy and Immunology (APJAI) is an online open access journal with the recent impact factor (2018) 1.747 APJAI published 4 times per annum (March, June, September, December). Four issues constitute one volume. APJAI publishes original research articles of basic science, clinical science and reviews on various aspects of allergy and immunology. This journal is an official journal of and published by the Allergy, Asthma and Immunology Association, Thailand. The scopes include mechanism, pathogenesis, host-pathogen interaction, host-environment interaction, allergic diseases, immune-mediated diseases, epidemiology, diagnosis, treatment and prevention, immunotherapy, and vaccine. All papers are published in English and are refereed to international standards.